Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 48, 2010, Pages 20780-20785

  Hafner, Christian ^a   Toll, Agustí ^b   Fernández Casado, Alejandro ^b   Earl, Julie ^b   Marqués, Miriam ^c   Acquadro, Francesco ^c   Méndez Pertuz, Marinela ^c   Urioste, Miguel ^c   Malats, Núria ^c   Burns, Julie E ^d   Knowles, Margaret A ^d   Cigudosa, Juan C ^c   Hartmann, Arndt ^e   Vogt, Thomas ^a   Landthaler, Michael ^a   Pujol, Ramón M ^b   Real, Francisco X ^c,f  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUBERIN;

CHROMOSOME INACTIVATION; CLINICAL ARTICLE; CLONAL VARIATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC STABILITY; HUMAN; MOLECULAR CLONING; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; SEBORRHEIC KERATOSIS; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 78650582977     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008365107     Document Type: Article

References (59)

1. Hafner C, Vogt T (2008) Seborrheic keratosis. J Dtsch Dermatol Ges 6:664-677.
2. Happle R, Rogers M (2002) Epidermal nevi. Adv Dermatol 18:175-201.
3. Happle R (1993) Mosaicism in human skin. Understanding the patterns and mechanisms. Arch Dermatol 129:1460-1470.
4. Hafner C, et al. (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 116:2201-2207.
5. Hernández S, et al. (2007) Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol 127:1664-1666.
6. Hafner C, et al. (2007) Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 104:13450-13454.
7. Logié A, et al. (2005) Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 14:1153-1160.
8. Toll A, Real FX (2008) Somatic oncogenic mutations, benign skin lesions and cancer progression: Where to look next? Cell Cycle 7:2674-2681.
9. Pollock PM, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
10. Krengel S, Hauschild A, Schäfer T (2006) Melanoma risk in congenital melanocytic naevi: A systematic review. Br J Dermatol 155:1-8.
11. Vajo Z, Francomano CA, Wilkin DJ (2000) The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 21:23-39.
12. Chesi M, et al. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264.
13. Cappellen D, et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20.
14. Naski MC, Wang Q, Xu J, Ornitz DM (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13:233-237.
15. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149.
16. Hafner C, et al. (2010) FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp Cell Res 316:2008-2016.
17. Rosenberger G, Meien S, Kutsche K (2009) Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. Hum Mutat 30:352-362.
18. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y (2008) The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29:992-1006.
19. Liaw D, et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67.
20. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004.
21. Hornigold N, et al. (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18:2657-2661.
22. Carpten JD, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
23. Jebar AH, et al. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218-5225.
24. Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103:1475-1479.
25. Bernard-Pierrot I, et al. (2006) Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27:740-747.
26. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430.
27. Hernández S, et al. (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24:3664-3671.
28. van Rhijn BW, et al. (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21:1912-1921.
29. Henikoff S, Henikoff JG (1992) Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 89:10915-10919.
30. Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185:862-864.
31. Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14(Spec No 2):R251-R258.
32. Lee JC, et al. (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3:e485.
33. Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. Cell 130:223-233.
34. Collado M, Serrano M (2006) The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6:472-476.
35. Collado M, et al. (2005) Tumour biology: Senescence in premalignant tumours. Nature 436:642.
36. Wood LD, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
37. Jones S, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
38. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
39. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
40. Tavormina PL, et al. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321-328.
41. López-Knowles E, et al. (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404.
42. Zhao L, Vogt PK (2010) Hot-spot mutations in p110alpha of phosphatidylinositol 3- kinase (pI3K): Differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9:596-600.
43. Pang H, et al. (2009) Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3- kinase. Cancer Res 69:8868-8876.
44. Kalinsky K, et al. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049-5059.
45. Collado M, SerranoM(2010) Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 10:51-57.
46. Michaloglou C, et al. (2005) BRAF E600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724.
47. Courtois-Cox S, et al. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:459-472.
48. Majumder PK, et al. (2008) A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14:146-155.
49. Di Micco R, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444:638-642.
50. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552.
51. Happle R (1995) Epidermal nevus syndromes. Semin Dermatol 14:111-121.
52. Mandinova A, et al. (2009) A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest 119: 3127-3137.
53. Kilpivaara O, et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455-459.
54. Olcaydu D, et al. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450-454.
55. Kiemeney LA, et al. (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 42:415-419.
56. Chaturvedi V, Chu MD S, Carrol BS M, Brenner BS JW, Nickoloff BJ (2002) Estimation of size of clonal unit for keratinocytes in normal human skin. Arch Pathol Lab Med 126:420-424.
57. Nakamura H, et al. (2001) Clonal nature of seborrheic keratosis demonstrated by using the polymorphism of the human androgen receptor locus as a marker. J Invest Dermatol 116:506-510.
58. Greaves M (2003) Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol 7: 233-245.
59. Wiemels JL, et al. (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354:1499-1503.